Chemcrux Enterprises Ltd

Chemcrux Enterprises Ltd. is informing shareholders, particularly those without registered email addresses, about the 30th Annual General Meeting (AGM) scheduled for September 17, 2026. The AGM will be conducted via Video Conferencing/Other Audio Visual Means. The Notice and Annual Report for the Financial Year 2025-26 are accessible via provided web links and on the company's website. Shareholders are urged to register their email addresses for prompt communication.

Chemcrux Enterprises Ltd has issued a communication to its shareholders regarding the Tax Deducted at Source (TDS) on the final dividend for the Financial Year 2025-26. The Board of Directors recommended a dividend of Re. 1/- per equity share, subject to approval at the AGM on September 17, 2026. The dividend will be paid by October 17, 2026. The company will deduct TDS at applicable rates as per the Income-tax Act, 2025. For resident individual shareholders, TDS is 10% if the dividend exceeds Rs. 10,000, unless Form 121 is submitted. Shareholders are urged to update their PAN, bank details, and Aadhaar linkage to avoid higher TDS rates.

Chemcrux Enterprises Ltd has announced the calendar of events for its 30th Annual General Meeting (AGM), scheduled to be held on September 17, 2026, at 2:00 PM IST via Video Conference/Other Audio-Visual Means. Key dates include the cut-off for determining shareholders for notice dispatch (August 14, 2026) and e-voting eligibility (September 10, 2026). The book closure period is set from September 11 to September 17, 2026. The e-voting period will be from September 14 to September 16, 2026. This AGM will also determine dividend eligibility, if declared.

Chemcrux Enterprises Ltd has announced that the Board of Directors has fixed September 10, 2026, as the record date for determining shareholders eligible for the final dividend. This dividend, recommended by the directors for the financial year ended March 31, 2026, will be declared at the 30th Annual General Meeting (AGM) scheduled for September 17, 2026. Shareholders whose names appear in the company's register by the close of business on September 10, 2026, will be entitled to the dividend, if declared. The payment is expected within 30 days of the AGM, on or before October 17, 2026.

Chemcrux Enterprises Ltd. has announced its 30th Annual General Meeting (AGM) will be held on Thursday, September 17, 2026, at 2:00 PM IST. The meeting will be conducted through Video Conference/Other Audio Visual Means (VC/OAVM) in compliance with regulatory circulars. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY 2025-26, declaration of a final dividend of 10% (Re. 1 per equity share), re-appointment of a director retiring by rotation, and approval of remuneration for the Whole Time Director designated as Executive Chairman for a two-year period starting January 1, 2027, with a cap of Rs. 3 Crores per annum. The Annual Report for FY 2025-26 and the AGM notice are available electronically and on the company's website.

Chemcrux Enterprises Ltd has submitted its Annual Report for the Financial Year 2025-26, as per SEBI regulations. The report includes the Notice of the 30th Annual General Meeting (AGM) scheduled for Thursday, 17th September, 2026, at 02:00 P.M. IST, to be conducted via Video Conference/Other Audio Visual Means. The Annual Report is being distributed via email to members and is also available on the company's website. The company, a manufacturer of intermediates for API, Dyes & Pigments for 40 years, also detailed its Board of Directors, Key Managerial Personnel, Board Committees, and Auditors. The report covers various sections including financial statements, corporate governance, and CSR activities.

Chemcrux Enterprises Ltd announced the resignation of Mrs. Sidhdhi Girishkumar Shah, a Non-Executive, Non-Independent Director, effective August 4, 2026. The resignation was accepted by the Board of Directors at a meeting held on August 4, 2026. Mrs. Shah cited pre-occupation as the reason for her resignation and confirmed there are no other material reasons. She will also step down as Chairperson of the Stakeholders Relationship Committee. The company has provided necessary disclosures as per SEBI regulations.

Chemcrux Enterprises Ltd announced the appointment of Ms. Zarna Pankaj Thakar as an Additional Director (Non-Executive, Independent) effective August 4, 2026. Her tenure is for one year, concluding on August 3, 2027, and is subject to shareholder approval at the upcoming Annual General Meeting (AGM). Ms. Thakar brings over 10 years of experience as a practicing Cost and Management Accountant, advising listed companies and corporations on financial oversight, strategic cost management, and business transformation. She is the founder of Zarna Thakar & Associates and holds qualifications including CMA, US CMA, and B.Com. She is not related to any existing directors and has no shareholding in the company. Her remuneration will be limited to sitting fees for meetings and other approved payments.

Chemcrux Enterprises' consolidated PAT for Q1 FY27 came in at ₹0.51 Cr on revenue of ₹21.94 Cr, against a near-nil ₹0.09 Cr profit a year ago — a YoY turnaround, but off such a thin base that the percentage gain (+445%) overstates the underlying improvement. Sequentially, the print is weaker: revenue fell 9.6% and PAT fell 72.7% from Q4 FY26's ₹24.28 Cr revenue and ₹1.85 Cr PAT, and net margin compressed to 2.29% of total income from 7.51% last quarter (still above the 0.55% margin a year ago). The margin squeeze sits mostly below the operating line: consolidated PBT of ₹0.98 Cr trails standalone PBT of ₹1.85 Cr by ₹0.87 Cr, driven by higher finance costs and depreciation from subsidiary Kalichem Private Limited, plus lower other income at the group level. Standalone core profitability actually held up well — ₹1.37 Cr PAT and EPS of ₹0.93 versus consolidated EPS of ₹0.34 — meaning the group-level miss is a Kalichem-specific drag rather than a deterioration in the core bulk drug intermediates business. This lines up with Kalichem's May 2026 filing of a CTE amendment for inorganic chemicals, consistent with ramp-up costs ahead of expanded capacity. The quarter's employee expense also carries a proportionate charge for the 1,07,700 ESOPs granted on 15 May 2026 (1-year vesting, ₹10 exercise price), per the filing's notes. There is no formal analyst coverage of Chemcrux — a web check found zero analysts submitting estimates for the stock — so the print cannot be benchmarked against street consensus; vsStreet is unknown. The company also carries no prior formal guidance or outlook on record in our data, and no management press release accompanied this filing, so there is no stated targets to grade the quarter against. Other developments this quarter include the board's approval of a 10% final FY26 dividend and the incorporation of a wholly-owned non-profit subsidiary, Chemcrux Foundation (17 July 2026) — neither has a direct bearing on the P&L. Going into Q2 FY27, the read is: standalone operations are stable to improving YoY, but consolidated results will stay under pressure until Kalichem's ramp-up costs are absorbed by higher utilisation or revenue contribution.

Chemcrux Enterprises Ltd announced that its Board of Directors met on August 4, 2026, to approve the unaudited standalone and consolidated financial results for the first quarter of the fiscal year 2026-27, ending June 30, 2026. The Board also approved the Limited Review Report. Additionally, the Board has scheduled the 30th Annual General Meeting (AGM) for September 17, 2026, to be held via video conference. The meeting commenced at 5:00 PM and concluded at 7:20 PM.